[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Home Depot, Boeing & Progressive",
    "summary": "Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.",
    "url": "https://finnhub.io/api/news?id=ce3b197c03ec4aef3fc81ffb23e9bad7d7ed647314e38fe9b38e1da61c130659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760740920,
      "headline": "Top Analyst Reports for Home Depot, Boeing & Progressive",
      "id": 137133822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.",
      "url": "https://finnhub.io/api/news?id=ce3b197c03ec4aef3fc81ffb23e9bad7d7ed647314e38fe9b38e1da61c130659"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=109309b1a2a7ff703b476b1f36b4997acd290b8bc272a4aa9ca22467cdc5abec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760737502,
      "headline": "Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 137162463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=109309b1a2a7ff703b476b1f36b4997acd290b8bc272a4aa9ca22467cdc5abec"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Is Finally Rallying. Why Mizuho’s Jared Holz Is Optimistic This Time.",
    "summary": "Barron’s called Holz to ask about what’s happened to the biotech sector since our healthcare roundtable.",
    "url": "https://finnhub.io/api/news?id=f553f6fa35e1792518d8adc49b5e0963970986041fb8ed7049ec0284893ebbd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760724120,
      "headline": "Biotech Is Finally Rallying. Why Mizuho’s Jared Holz Is Optimistic This Time.",
      "id": 137162464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Barron’s called Holz to ask about what’s happened to the biotech sector since our healthcare roundtable.",
      "url": "https://finnhub.io/api/news?id=f553f6fa35e1792518d8adc49b5e0963970986041fb8ed7049ec0284893ebbd6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d85bd57808d5afa6e322f87b534d058d95e15b291f3f72f26857e9ea4a652701",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718960,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 137139328,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d85bd57808d5afa6e322f87b534d058d95e15b291f3f72f26857e9ea4a652701"
    }
  },
  {
    "ts": null,
    "headline": "3 Price Catalysts For Eli Lilly",
    "summary": "I go over 3 potential catalysts that could drive Eli Lilly's stock price up... or down. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=3084c73fd3836a539b5dae26c559828ff74a321f7ecc65300f09e602dacc2dec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718383,
      "headline": "3 Price Catalysts For Eli Lilly",
      "id": 137129254,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I go over 3 potential catalysts that could drive Eli Lilly's stock price up... or down. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=3084c73fd3836a539b5dae26c559828ff74a321f7ecc65300f09e602dacc2dec"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?",
    "summary": "JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.",
    "url": "https://finnhub.io/api/news?id=c80dc98882d67c760939c3c40cce52481a23d1b0d066f366406a84fa547965d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717460,
      "headline": "Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?",
      "id": 137127520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.",
      "url": "https://finnhub.io/api/news?id=c80dc98882d67c760939c3c40cce52481a23d1b0d066f366406a84fa547965d1"
    }
  },
  {
    "ts": null,
    "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
    "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
    "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703531,
      "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
      "id": 137126958,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253774892/image_1253774892.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
      "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain",
    "summary": "DURHAM, N.C., October 17, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically signifi",
    "url": "https://finnhub.io/api/news?id=07220e928f12cba8ea1ca340d099768190a7c8e4e5122219437b76169e24c000",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760698800,
      "headline": "ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain",
      "id": 137125861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "DURHAM, N.C., October 17, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically signifi",
      "url": "https://finnhub.io/api/news?id=07220e928f12cba8ea1ca340d099768190a7c8e4e5122219437b76169e24c000"
    }
  }
]